M. GIRARDIN, S. G. OUELLET, D. GAUVREAU, J. C. MOORE, G. HUGHES, P. N. DEVINE, P. D. O'SHEA, L.-C. CAMPEAU* (MERCK FROSST CENTER FOR THERAPEUTIC RESEARCH, KIRKLAND, CANADA AND MERCK RESEARCH LABORATORIES, RAHWAY, USA)
 Convergent Kilogram-Scale Synthesis of Dual Orexin Receptor Antagonist
Org. Process Res. Dev. **2013**, *17*, 61–68.

Synthesis of MK-6096

Catalytic cycle for the transamination to piperidone **D**:

Significance: The orexins are peptides that act as neurotransmitters in the central nervous system. MK-6096 is a dual orexin receptor antagonist that is a candidate for the treatment of insomnia. A noteworthy feature of the synthesis depicted is the biocatalytic transamination reaction on prochiral substrate **A** using a three-enzyme cocktail that delivers piperidinone **B** (>99% ee) on a multikilogram scale.

SYNFACTS Contributors: Philip Kocienski
 Synfacts 2013, 9(4), 0355 Published online: 15.03.2013
 DOI: 10.1055/s-0032-1318322; Reg-No.: K01413SF

Comment: The diastereoisomeric ratio of the α -hydroxymethyl lactam (dr = 1.7:1) was improved to >40:1 by reduction of the lactam followed by salt formation using D-(+)-camphorsulfonic acid [D-(+)-CSA]. For the development of transaminase ATA-117 in the manufacture of sitagliptin, see: C. K. Savile et al. *Science* **2010**, 329, 305.